Citalopram Orion 20 mg Norge - norsk - Statens legemiddelverk

citalopram orion 20 mg

orion corporation orion pharma - citalopramhydrobromid - tablett, filmdrasjert - 20 mg

Fluoxetine Orion 20 mg Norge - norsk - Statens legemiddelverk

fluoxetine orion 20 mg

orion corporation - espoo - fluoksetinhydroklorid - kapsel, hard - 20 mg

Imatinib Koanaa Den europeiske union - norsk - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pasienter som har en lav eller svært lav risiko for tilbakefall bør ikke får adjuvant behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. bortsett fra i nydiagnostisert kronisk fase kml, det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer.

Mysimba Den europeiske union - norsk - EMA (European Medicines Agency)

mysimba

orexigen therapeutics ireland limited - bupropionhydroklorid, naltrexon hydroklorid - obesity; overweight - antiobesity preparater, ekskl. diettprodukter - mysimba er angitt, som et supplement til en redusert calorie diett og økt fysisk aktivitet for forvaltning av vekt hos voksne pasienter (≥18 år) med en innledende body mass index (bmi) på≥ 30 kg/m2 (fedme), eller≥ 27 kg/m2 og < 30 kg/m2 (overvektig) i nærvær av en eller flere vekt-relaterte co morbidities (e. , type 2 diabetes, dyslipidaemia, eller kontrollert hypertensjon)behandling med mysimba bør være avviklet etter 16 uker hvis pasienter ikke har tapt minst 5% av sin opprinnelige kroppsvekt.

Fluoxetin Viatris 20 mg Norge - norsk - Statens legemiddelverk

fluoxetin viatris 20 mg

viatris limited - fluoksetinhydroklorid - kapsel, hard - 20 mg

Fluoxetin Sandoz 20 mg Norge - norsk - Statens legemiddelverk

fluoxetin sandoz 20 mg

sandoz - københavn - fluoksetinhydroklorid - dispergerbar tablett - 20 mg

Fluoxetine Vitabalans 20 mg Norge - norsk - Statens legemiddelverk

fluoxetine vitabalans 20 mg

vitabalans oy - fluoksetinhydroklorid - tablett, filmdrasjert - 20 mg

Lerkanidipin Actavis 20 mg Norge - norsk - Statens legemiddelverk

lerkanidipin actavis 20 mg

actavis group ptc ehf - lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg

Lerkanidipin Actavis 10 mg Norge - norsk - Statens legemiddelverk

lerkanidipin actavis 10 mg

actavis group ptc ehf - lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg

Zanidip 10 mg Norge - norsk - Statens legemiddelverk

zanidip 10 mg

recordati ireland limited - lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg